Back to top
more

Aclaris Therapeutics, Inc. (ACRS)

(Delayed Data from NSDQ)

$1.88 USD

1.88
361,372

+0.15 (8.67%)

Updated Dec 13, 2019 03:56 PM ET

After-Market: $1.90 +0.02 (1.06%) 7:03 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | D Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Rigel Gets Positive CHMP Review for Thrombocytopenia Drug

The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.

RDHL ACRS JAZZ RIGL

Zacks Equity Research

Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRS

Zacks Equity Research

Company News for Oct 17, 2019

Companies In The News Are: GM, ACRS, MGM, AVD

MGM GM AVD ACRS

Zacks Equity Research

Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

AGN DERM RIGL ACRS

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for October 3rd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 3rd.

ALLY ALGT ACRS ACA

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for September 27th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 27th.

ALLY AEP ACRS

Zacks Equity Research

Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aclaris Therapeutics, Inc. (ACRS).

ACRS

Zacks Equity Research

Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ACRS

Zacks Equity Research

Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know

Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACRS

Zacks Equity Research

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.

JNJ PCRX ACRS ZTS

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 6.49% and 1.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ACRS

Zacks Equity Research

Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance

Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.

GALT ZTS ACRS PTLA

Zacks Equity Research

Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRS

Zacks Equity Research

Aclaris Therapeutics Enters Oversold Territory

Aclaris Therapeutics has been on a bit of a cold streak lately.

ACRS

Zacks Equity Research

What Makes Aclaris (ACRS) a New Buy Stock

Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACRS

Zacks Equity Research

Rigel Initiates Enrollment in Pivotal Blood Disorder Study

Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.

AZN KALV RIGL ACRS

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ACRS

Zacks Equity Research

Aclaris Therapeutics Enters Oversold Territory

Aclaris Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ACRS

Zacks Equity Research

Aclaris Therapeutics (ACRS) Enters Oversold Territory

Aclaris Therapeutics, Inc. (ACRS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

ACRS

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 15.20% and 3.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

ACRS

Zacks Equity Research

Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRS

Zacks Equity Research

Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug

The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.

UTHR RIGL ENDP ACRS

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -6.32% and 33.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

ACRS

Zacks Equity Research

Aclaris' Alopecia Candidate Gets Fast Track Designation

The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.

BLRX ACRX ACRS CLGN

Zacks Equity Research

Aclaris Stock Up on JAK Inhibitor's Encouraging Activity

Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.

BLRX JAZZ ACRS CLGN